PortalPublikationenNew AHA and ACC guidelines on the treatment of blood cholest...

New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk

Standard

New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. / Klose, Gerald; Beil, Frank Ulrich; Dieplinger, Hans; von Eckardstein, Arnold; Föger, Bernhard; Gouni-Berthold, Ioanna; Heigl, Franz; Koenig, Wolfgang; Kostner, Gert M; Landmesser, Ulf; Laufs, Ulrich; Leistikow, Frank; März, Winfried; Noll, Georg; Parhofer, Klaus G; Paulweber, Bernhard; Riesen, Walter F; Schaefer, Jürgen R; Steinhagen-Thiessen, Elisabeth; Steinmetz, Armin; Toplak, Hermann; Wanner, Christoph; Windler, Eberhard; American Heart Association, American College of Cardiology.

in: WIEN KLIN WOCHENSCHR, Jahrgang 126, Nr. 5-6, 03.2014, S. 169-175.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung

Harvard

Klose, G, Beil, FU, Dieplinger, H, von Eckardstein, A, Föger, B, Gouni-Berthold, I, Heigl, F, Koenig, W, Kostner, GM, Landmesser, U, Laufs, U, Leistikow, F, März, W, Noll, G, Parhofer, KG, Paulweber, B, Riesen, WF, Schaefer, JR, Steinhagen-Thiessen, E, Steinmetz, A, Toplak, H, Wanner, C, Windler, E & American Heart Association, American College of Cardiology 2014, 'New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk', WIEN KLIN WOCHENSCHR, Jg. 126, Nr. 5-6, S. 169-175. https://doi.org/10.1007/s00508-014-0513-9

APA

Klose, G., Beil, F. U., Dieplinger, H., von Eckardstein, A., Föger, B., Gouni-Berthold, I., Heigl, F., Koenig, W., Kostner, G. M., Landmesser, U., Laufs, U., Leistikow, F., März, W., Noll, G., Parhofer, K. G., Paulweber, B., Riesen, W. F., Schaefer, J. R., Steinhagen-Thiessen, E., ... American Heart Association, American College of Cardiology (2014). New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. WIEN KLIN WOCHENSCHR, 126(5-6), 169-175. https://doi.org/10.1007/s00508-014-0513-9

Vancouver

Klose G, Beil FU, Dieplinger H, von Eckardstein A, Föger B, Gouni-Berthold I et al. New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk. WIEN KLIN WOCHENSCHR. 2014 Mär;126(5-6):169-175. https://doi.org/10.1007/s00508-014-0513-9

Bibtex

@article{843799e53ad049e2a9c86004c843b77b,
title = "New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk",
abstract = "After the publication of the new guidelines of the European Society of Cardiology and the European Atherosclerosis Society for the prevention and treatment of dyslipidemias (Eur Heart J 32:1769-1818, 2011; Eur Heart J 33:1635-1701, 2012), a group of authors has recently published on behalf of the American Heart Association and the American College of Cardiology guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk (Circulation 2013). These new guidelines are supposed to replace the until now widely accepted, at least in the USA, recommendations of the National Cholesterol Education Program Adult Treatment Panel III from the years 2002 (Circulation 106:3143-3421, 2002) and 2004 (Circulation 110:227-39, 2004). Furthermore, they claim to be based mainly on hard evidence derived from the interpretation of results of prospective randomized controlled trials. This Joint Position Statement of the Society for the Prevention of Cardiovascular Diseases e.V. (D.A.CH), the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society of Cardiology concludes that the use of individualized prevention strategies based on specific indications and LDL cholesterol target concentrations, a strategy whose worth has been widely proven and accepted for more than a decade in Europe, should not be given up.",
keywords = "Adult, Aged, Atherosclerosis/blood, Cause of Death, Cholesterol, LDL/blood, Combined Modality Therapy, Diabetes Mellitus, Type 2/blood, Europe, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Hypercholesterolemia/blood, Male, Middle Aged, Risk Reduction Behavior, Survival Rate",
author = "Gerald Klose and Beil, {Frank Ulrich} and Hans Dieplinger and {von Eckardstein}, Arnold and Bernhard F{\"o}ger and Ioanna Gouni-Berthold and Franz Heigl and Wolfgang Koenig and Kostner, {Gert M} and Ulf Landmesser and Ulrich Laufs and Frank Leistikow and Winfried M{\"a}rz and Georg Noll and Parhofer, {Klaus G} and Bernhard Paulweber and Riesen, {Walter F} and Schaefer, {J{\"u}rgen R} and Elisabeth Steinhagen-Thiessen and Armin Steinmetz and Hermann Toplak and Christoph Wanner and Eberhard Windler and {American Heart Association, American College of Cardiology}",
year = "2014",
month = mar,
doi = "10.1007/s00508-014-0513-9",
language = "English",
volume = "126",
pages = "169--175",
journal = "WIEN KLIN WOCHENSCHR",
issn = "0043-5325",
publisher = "Springer Wien",
number = "5-6",

}

RIS

TY - JOUR

T1 - New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk

AU - Klose, Gerald

AU - Beil, Frank Ulrich

AU - Dieplinger, Hans

AU - von Eckardstein, Arnold

AU - Föger, Bernhard

AU - Gouni-Berthold, Ioanna

AU - Heigl, Franz

AU - Koenig, Wolfgang

AU - Kostner, Gert M

AU - Landmesser, Ulf

AU - Laufs, Ulrich

AU - Leistikow, Frank

AU - März, Winfried

AU - Noll, Georg

AU - Parhofer, Klaus G

AU - Paulweber, Bernhard

AU - Riesen, Walter F

AU - Schaefer, Jürgen R

AU - Steinhagen-Thiessen, Elisabeth

AU - Steinmetz, Armin

AU - Toplak, Hermann

AU - Wanner, Christoph

AU - Windler, Eberhard

AU - American Heart Association, American College of Cardiology

PY - 2014/3

Y1 - 2014/3

N2 - After the publication of the new guidelines of the European Society of Cardiology and the European Atherosclerosis Society for the prevention and treatment of dyslipidemias (Eur Heart J 32:1769-1818, 2011; Eur Heart J 33:1635-1701, 2012), a group of authors has recently published on behalf of the American Heart Association and the American College of Cardiology guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk (Circulation 2013). These new guidelines are supposed to replace the until now widely accepted, at least in the USA, recommendations of the National Cholesterol Education Program Adult Treatment Panel III from the years 2002 (Circulation 106:3143-3421, 2002) and 2004 (Circulation 110:227-39, 2004). Furthermore, they claim to be based mainly on hard evidence derived from the interpretation of results of prospective randomized controlled trials. This Joint Position Statement of the Society for the Prevention of Cardiovascular Diseases e.V. (D.A.CH), the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society of Cardiology concludes that the use of individualized prevention strategies based on specific indications and LDL cholesterol target concentrations, a strategy whose worth has been widely proven and accepted for more than a decade in Europe, should not be given up.

AB - After the publication of the new guidelines of the European Society of Cardiology and the European Atherosclerosis Society for the prevention and treatment of dyslipidemias (Eur Heart J 32:1769-1818, 2011; Eur Heart J 33:1635-1701, 2012), a group of authors has recently published on behalf of the American Heart Association and the American College of Cardiology guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk (Circulation 2013). These new guidelines are supposed to replace the until now widely accepted, at least in the USA, recommendations of the National Cholesterol Education Program Adult Treatment Panel III from the years 2002 (Circulation 106:3143-3421, 2002) and 2004 (Circulation 110:227-39, 2004). Furthermore, they claim to be based mainly on hard evidence derived from the interpretation of results of prospective randomized controlled trials. This Joint Position Statement of the Society for the Prevention of Cardiovascular Diseases e.V. (D.A.CH), the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society of Cardiology concludes that the use of individualized prevention strategies based on specific indications and LDL cholesterol target concentrations, a strategy whose worth has been widely proven and accepted for more than a decade in Europe, should not be given up.

KW - Adult

KW - Aged

KW - Atherosclerosis/blood

KW - Cause of Death

KW - Cholesterol, LDL/blood

KW - Combined Modality Therapy

KW - Diabetes Mellitus, Type 2/blood

KW - Europe

KW - Female

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Hypercholesterolemia/blood

KW - Male

KW - Middle Aged

KW - Risk Reduction Behavior

KW - Survival Rate

U2 - 10.1007/s00508-014-0513-9

DO - 10.1007/s00508-014-0513-9

M3 - Other (editorial matter etc.)

C2 - 24615676

VL - 126

SP - 169

EP - 175

JO - WIEN KLIN WOCHENSCHR

JF - WIEN KLIN WOCHENSCHR

SN - 0043-5325

IS - 5-6

ER -